Temocillin: Applications in Antimicrobial Stewardship As a Potential Carbapenem-Sparing Antibiotic

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2022 Apr 23

PMID 35453244

Authors

Tommaso Lupia

Ilaria De Benedetto

Giacomo Stroffolini

Stefano Di Bella

Simone Mornese Pinna

Verena Zerbato

Barbara Rizzello

Roberta Bosio

Nour Shbaklo

Silvia Corcione

Francesco Giuseppe De Rosa

Affiliations

Soon will be listed here.

Abstract

Temocillin is an old antibiotic, but given its particular characteristics, it may be a suitable alternative to carbapenems for treating infections due to ESBL-producing and uncomplicated UTI due to KPC-producers. In this narrative review, the main research question was to summarize current evidence on temocillin and its uses in infectious diseases. A search was run on PubMed using the terms ('Temocillin' [Mesh]) AND ('Infection' [Mesh]). Current knowledge regarding temocillin in urinary tract infection, blood-stream infections, pneumonia, intra-abdominal infections, central nervous system infections, skin and soft tissues infections, surgical sites infections and osteoarticular Infections were summarized. Temocillin retain a favourable profile on microbiota and risk of infections and could be an option for treating outpatients. Temocillin may be a valuable tool to treat susceptible pathogens and for which a carbapenem could be spared. Other advantages in temocillin use are that it is well-tolerated; it is associated with a low rate of infections; it is active against ESBL, AmpC, and KPC-producing ; and it can be used in the OPAT clinical setting.

Citing Articles

Preserving the antimicrobial arsenal: exploring alternatives to carbapenems in ESBL battles within the southeast of Ireland.

Ali S, Tobin A, Lapthorne S, Collison M, Murphy D, Chan G J Med Microbiol. 2025; 74(2).

PMID: 39907141 PMC: 11796091. DOI: 10.1099/jmm.0.001955.

Synergistic Activity of Temocillin and Fosfomycin Combination against KPC-Producing Clinical Isolates.

Costantino V, Principe L, Mehat J, Busetti M, Piccirilli A, Perilli M Antibiotics (Basel). 2024; 13(6).

PMID: 38927192 PMC: 11200827. DOI: 10.3390/antibiotics13060526.

The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy.

Rusu A, Moga I, Uncu L, Hancu G Pharmaceutics. 2023; 15(11).

PMID: 38004534 PMC: 10675556. DOI: 10.3390/pharmaceutics15112554.

Pharmacokinetics of Antimicrobials in Children with Emphasis on Challenges Faced by Low and Middle Income Countries, a Clinical Review.

Meesters K, Alemayehu T, Benou S, Buonsenso D, Decloedt E, Pillay-Fuentes Lorente V Antibiotics (Basel). 2023; 12(1).

PMID: 36671218 PMC: 9854442. DOI: 10.3390/antibiotics12010017.

Real-life temocillin use in Greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: a multicentre retrospective study.

Dinh A, Duran C, Singh S, Tesmoingt C, Bouabdallah L, Hamon A JAC Antimicrob Resist. 2023; 5(1):dlac132.

PMID: 36601547 PMC: 9798080. DOI: 10.1093/jacamr/dlac132.

References

Vandecasteele S, Miranda Bastos A, Capron A, Spinewine A, Tulkens P, Van Bambeke F . Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients. Int J Antimicrob Agents. 2015; 46(6):660-5. DOI: 10.1016/j.ijantimicag.2015.09.005. View

Slocombe B, Basker M, BENTLEY P, Clayton J, Cole M, Comber K . BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans. Antimicrob Agents Chemother. 1981; 20(1):38-46. PMC: 181629. DOI: 10.1128/AAC.20.1.38. View

Peirano G, Pitout J . Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options. Drugs. 2019; 79(14):1529-1541. DOI: 10.1007/s40265-019-01180-3. View

Verbist L, Verhaegen J . Effect of temocillin in combination with other beta-lactam antibiotics. Antimicrob Agents Chemother. 1984; 25(1):142-4. PMC: 185455. DOI: 10.1128/AAC.25.1.142. View

Wittke R, Adam D, Klein H . Therapeutic results and tissue concentrations of temocillin in surgical patients. Drugs. 1985; 29 Suppl 5:221-6. DOI: 10.2165/00003495-198500295-00049. View

Loza E, Romero-Vivas J, Bouza E . Temocillin. In vitro activity compared with other antibiotics. Drugs. 1985; 29 Suppl 5:91-7. DOI: 10.2165/00003495-198500295-00018. View

Barton E, Flanagan P, Hill S . Spinal infection caused by ESBL-producing Klebsiella pneumoniae treated with temocillin. J Infect. 2008; 57(4):347-9. DOI: 10.1016/j.jinf.2008.08.001. View

Chen H, Williams J . The activity of temocillin against Enterobacteriaceae, Pseudomonas and Haemophilus influenzae. Drugs. 1985; 29 Suppl 5:85-90. DOI: 10.2165/00003495-198500295-00017. View

Vanhoof R, Berin C, Carpentier M, Fagnart O, Glupczynski Y, Mans I . Comparative in vitro activity of temocillin and other antimicrobial agents against Enterobacteriaceae isolated from patients admitted to five Belgian hospitals. Acta Clin Belg. 2002; 56(6):354-9. DOI: 10.1179/acb.2001.053. View

10.

Wise R, Donovan I, Drumm J, Dyas A, Cross C . The intraperitoneal penetration of temocillin. J Antimicrob Chemother. 1983; 12(1):93-6. DOI: 10.1093/jac/12.1.93. View

11.

Bolivar R, Weaver S, Bodey G . Comparative in vitro study of temocillin (BRL 17421), a new penicillin. Antimicrob Agents Chemother. 1982; 21(4):641-5. PMC: 181957. DOI: 10.1128/AAC.21.4.641. View

12.

Layios N, Visee C, Mistretta V, Denooz R, Maes N, Descy J . Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions. Antimicrob Agents Chemother. 2022; 66(3):e0205221. PMC: 8923201. DOI: 10.1128/AAC.02052-21. View

13.

Woodnutt G, Catherall E, Kernutt I, Mizen L . Temocillin efficacy in experimental Klebsiella pneumoniae meningitis after infusion into rabbit plasma to simulate antibiotic concentrations in human serum. Antimicrob Agents Chemother. 1988; 32(11):1705-9. PMC: 175955. DOI: 10.1128/AAC.32.11.1705. View

14.

Tarnberg M, Ostholm-Balkhed A, Monstein H, Hallgren A, Hanberger H, Nilsson L . In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis. 2011; 30(8):981-7. DOI: 10.1007/s10096-011-1183-4. View

15.

Lockley M, Brown R, Wise R . Pharmacokinetics and tissue penetration of temocillin. Drugs. 1985; 29 Suppl 5:106-8. DOI: 10.2165/00003495-198500295-00022. View

16.

Tjiam K, van Heijst B, van Joost T, Stolz E, Michel M . In vitro activity of temocillin (BRL 17421) against Chlamydia trachomatis. Eur J Clin Microbiol. 1984; 3(1):39-40. DOI: 10.1007/BF02032815. View

17.

Soubirou J, Rossi B, Couffignal C, Ruppe E, Chau F, Massias L . Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15. J Antimicrob Chemother. 2015; 70(5):1466-72. DOI: 10.1093/jac/dku542. View

18.

Woodford N, Pike R, Meunier D, Loy R, Hill R, Hopkins K . In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J Antimicrob Chemother. 2013; 69(2):564-7. DOI: 10.1093/jac/dkt383. View

19.

Berleur M, Guerin F, Massias L, Chau F, Poujade J, Cattoir V . Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli. J Antimicrob Chemother. 2018; 73(11):3074-3080. DOI: 10.1093/jac/dky283. View

20.

Lindsay G, Beattie A, Taylor E . Temocillin in the treatment of serious gram-negative infections. Drugs. 1985; 29 Suppl 5:191-3. DOI: 10.2165/00003495-198500295-00041. View